A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy (Q51562151)
Jump to navigation
Jump to search
scientific article published in January 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy |
scientific article published in January 2016 |
Statements
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. (English)
1 reference
John Y Li
1 reference
Samuel R Perry
1 reference
Vanessa Muniz-Medina
1 reference
Xinzhong Wang
1 reference
Leslie K Wetzel
1 reference
Marlon C Rebelatto
1 reference
Mary Jane Masson Hinrichs
1 reference
Binyam Z Bezabeh
1 reference
Ryan L Fleming
1 reference
Nazzareno Dimasi
1 reference
Hui Feng
1 reference
Dorin Toader
1 reference
Andy Q Yuan
1 reference
Lan Xu
1 reference
Jia Lin
1 reference
Changshou Gao
1 reference
Herren Wu
1 reference
Rakesh Dixit
1 reference
Jane K Osbourn
1 reference
Steven R Coats
1 reference
1 January 2016
1 reference
29
1 reference
1
1 reference
117-129
1 reference